Abstract:Lung cancer is the leading cause of cancer-related mortality worldwide. Despite progress in the treatment of non-small-cell lung cancer, there are limited treatment options for lung squamous cell carcinoma (LUSC), compared with lung adenocarcinoma. The present study investigated the disease mechanism of LUSC in order to identify key candidate genes for diagnosis and therapy. A total of three gene expression profiles (GSE19188, GSE21933 and GSE74706) were analyzed using GEO2R to identify common differentially expressed genes (DEGs). The DEGs were then investigated using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. A protein-protein interaction (PPI) network was constructed via the Search Tool for the Retrieval of Interacting Genes/Proteins, and visualized using Cytoscape software. The expression levels of the hub genes identified using CytoHubba were validated using the University of California, Santa Cruz (UCSC) database and the Human Protein Atlas. A Kaplan-Meier curve and Gene Expression Profiling Interactive Analysis were then employed to evaluate the associated prognosis and clinical pathological stage of the hub genes. Furthermore, non-coding RNA regulatory networks were constructed using the Gene-Cloud Biotechnology information website. A total of 359 common DEGs (155 upregulated and 204 downregulated) were identified, which were predominantly enriched in ‘mitotic nuclear division’, ‘cell division’, ‘cell cycle’ and ‘p53 signaling pathway’. The PPI network consisted of 257 nodes and 2,772 edges, and the most significant module consisted of 66 upregulated genes. A total of 19 hub genes exhibited elevated RNA levels, and 10 hub genes had elevated protein levels compared with normal lung tissues. The upregulation of five hub genes (CCNB1, CEP55, FOXM1, MKI67 and TYMS; defined in Table I) were significantly associated with poor overall survival and unfavorable clinical pathological stages. Various ncRNAs, such as C1orf220, LINC01561 and MGC39584, may also play important roles in hub-gene regulation. In conclusion, the present study provides further understanding of the pathogenesis of LUSC, and reveals CCNB1, CEP55, FOXM1, MKI67 and TYMS as potential biomarkers or therapeutic targets.

Clinical Value of Mir-182-5p in Lung Squamous Cell Carcinoma: a Study Combining Data from TCGA, GEO, and RT-qPCR Validation

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

Clinical Value and Potential Mechanism of Mirna-33A-5p in Lung Squamous Cell Carcinoma

Clinical Significance of High Expression of Mir-452-5p in Lung Squamous Cell Carcinoma.

Clinical Value of Mir-198-5p in Lung Squamous Cell Carcinoma Assessed Using Microarray and RT-qPCR

Identification Of Mir-133a-3p-Expression Signature And Probable Mechanism In Lung Squamous Cell Carcinoma: Insights From Integrated Analysis

Downregulation of Mir-125B-5p and Its Prospective Molecular Mechanism in Lung Squamous Cell Carcinoma.

Investigation of Mir-136-5p Key Target Genes and Pathways in Lung Squamous Cell Cancer Based on TCGA Database and Bioinformatics Analysis

Diagnosis Value of Aberrantly Expressed Microrna Profiles in Lung Squamous Cell Carcinoma: a Study Based on the Cancer Genome Atlas

Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data

Clinical Value and Prospective Pathway Signaling of MicroRNA-375 in Lung Adenocarcinoma: A Study Based on the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and Bioinformatics Analysis

The Clinical Value of Mir‐193a‐3p in Non‐small Cell Lung Cancer and Its Potential Molecular Mechanism Explored in Silico Using RNA‐sequencing and Microarray Data

Potential Targets and Clinical Value of Mir-490-5p in Hepatocellular Carcinoma: a Study Based on TCGA, Qrt-Pcr and Bioinformatics Analyses.

MiR-182-5p and its target HOXA9 in non-small cell lung cancer: a clinical and in-silico exploration with the combination of RT-qPCR, miRNA-seq and miRNA-chip

Characterization of Micrornas and Lncrnas in Early-Stage Squamous Cell Carcinoma Based on the Analysis of TCGA Datasets

Analysis of the Role and Regulation Mechanism of hsa-miR-147b in Lung Squamous Cell Carcinoma Based on The Cancer Genome Atlas Database

Down-regulation of Microrna-144-3p and Its Clinical Value in Non-Small Cell Lung Cancer: a Comprehensive Analysis Based on Microarray, Mirna-Sequencing, and Quantitative Real-Time PCR Data

Mir-1306 Promotes Lung Squamous Cell Carcinoma Progression and Predicts Clinical Prognosis of Patients.

Identification of 17 Mrnas and a Mirna As an Integrated Prognostic Signature for Lung Squamous Cell Carcinoma.

Up-Regulation Of Mir-182-5p Predicts Poor Prognosis In Patients With Lung Cancer And Associates With Tumor Cell Growth And Migration

Gene Regulation and Prognostic Indicators of Lung Squamous Cell Carcinoma: TCGA-derived Mirna/mrna Sequencing and DNA Methylation Data.